Navigation Links
University Hospital of Bordeaux Officially Opens New Electrophysiology Lab
Date:12/4/2007

New Lab Features Installation of Stereotaxis Magnetic Navigation System at

Prestigious Research Center

ST. LOUIS, Dec. 4 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today the official opening of the Stereotaxis Magnetic Navigation System at the new electrophysiology (EP) lab at the University Hospital of Bordeaux, France. The lab is headed by Professors Michel Haissaguerre and Pierre Jais, whose discovery of the ectopic foci that trigger atrial fibrillation (AF) in 1998 paved the way for new ablation techniques for more effectively treating this disease which affects millions of people worldwide.

The new EP lab was unveiled today in a ceremony at which Alain Heriaud, General Director of CHU of Bordeaux, Bevil Hogg, CEO of Stereotaxis and Alain Juppe, Mayor of Bordeaux and president of the board of directors of CHU of Bordeaux, presided.

"We are very enthusiastic about the present and future applications for the Stereotaxis system, which represents an engineering tour de force," said Professor Haissaguerre. "Today the Stereotaxis system allows stable and precise catheter positioning potentially better than manual manipulation. Our initial experience on atrial fibrillation using the magnetic irrigated catheter is very promising, suggesting notably the potential for a higher safety margin in comparison with conventional manipulation while maintaining at least equivalent efficacy."

"Our next goal is to achieve complete automation of the many different techniques necessary for catheter ablation of cardiac arrhythmias and particularly atrial fibrillation. We hope our partnership with Stereotaxis will be mutually beneficial in achieving our goals of further understanding and treating the most complex rhythm disturbances leading to better patient care," Professor Haissaguerre concluded.

"The installation of the Stereotaxis Niobe(R) system in Bordeaux represents a significant milestone for us, and we are particularly honored that the system has been installed at the University Hospital of Bordeaux, one of the leading research institutions in the world for electrophysiology," said Bevil Hogg, CEO of Stereotaxis. "We are also proud to note that Bordeaux has installed the Stereotaxis system with an Odyssey(TM) Network Solution. Odyssey is a powerful fully-networked user interface that consolidates the multiple information sources and systems of a traditional electrophysiology lab into one large screen with single mouse control, and has the potential to contribute significantly to procedure room simplification and work-flow productivity, and through its private network, to promote the dissemination of best practices worldwide."

"The recent launch of our partnered irrigated catheter has now expanded to multiple sites in Europe, and we are very pleased with the initial results," continued Mr. Hogg. "A significant number of cases using the irrigated catheter have now been performed, and we are gratified to note the high success rate in terms of outcomes and patient safety."

"Professor Haissaguerre and his team are pioneers in the discovery of new approaches to the treatment of AF and we look forward to using our collaboration with the Bordeaux team to advance scientific understanding and treatment of cardiac arrhythmias. We are honored to pay tribute to this esteemed team by participating in the opening of their new EP lab," concluded Mr. Hogg.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. Stereotaxis has research agreements with certain leading institutions worldwide, including Bordeaux, France. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada. Note that use of cardiac ablation catheters for treatment of atrial fibrillation is considered investigational in the United States.

About Forward Looking Statements

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. University of Iowa professor identifies new eating disorder
2. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
4. Tulane University to receive $14M for international HIV/AIDS program
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. Boston University School of Medicine researcher recipient of Memory Ride Grant
7. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
8. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
9. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... Journal of Oral Implantology – Tooth loss ... overall dental health, including complications with speech, eating, and overcompensation of mouth due to ... lost teeth. As the number of tooth replacements increase, it is imperative to design ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... in Hackensack, N.J. has been honored by Enterprising Women magazine as one ... recognizes the world’s top women business owners. Winners have demonstrated that they have ...
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor ... I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 6.35% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology: